Drug
BLU-5937 clinical trials
Also written Camlipixant and BLU-5937.
- studies test it
- 16
- open now
- 2
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the BLU-5937 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
16 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Bellus Health Inc. - a GSK company (13) · GlaxoSmithKline (3)
Often tested with
Tested in the same studies.
Dabigatran (1) · Gemfibrozil (1) · Rabeprazole (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses BLU-5937 is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)RecruitingPhase 2GlaxoSmithKlineNCT07519395Written as Camlipixant
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China ExtensionRecruitingPhase 3GlaxoSmithKlineNCT07650084Written as BLU-5937
- A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation PrototypesWithdrawnPhase 1GlaxoSmithKlineNCT07684586Written as Camlipixant
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughActive, not recruitingPhase 3Bellus Health Inc. - a GSK companyNCT05600777Written as BLU-5937
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompletedPhase 3Bellus Health Inc. - a GSK companyNCT05599191Written as BLU-5937
- A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of AgeCompletedPhase 1Bellus Health Inc. - a GSK companyNCT06222892Written as Camlipixant
- Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference FormulationCompletedPhase 1Bellus Health Inc. - a GSK companyNCT05570539Written as BLU-5937 IR
- Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and CamlipixantCompletedPhase 1Bellus Health Inc. - a GSK companyNCT05959447Written as Camlipixant
- A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy ParticipantsCompletedPhase 1Bellus Health Inc. - a GSK companyNCT06497517Written as GSK5464714- Camlipixant
- Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCompletedPhase 1Bellus Health Inc. - a GSK companyNCT05899829Written as Camlipixant
- Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian SubjectsCompletedPhase 1Bellus Health Inc. - a GSK companyNCT06179537Written as BLU-5937
- A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic DermatitisCompletedPhase 2Bellus Health Inc. - a GSK companyNCT04693195Written as BLU-5937
- Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937CompletedPhase 1Bellus Health Inc. - a GSK companyNCT05244759Written as [14C]-BLU-5937
- Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompletedPhase 2Bellus Health Inc. - a GSK companyNCT04678206Written as BLU-5937
- A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic CoughTerminatedPhase 2Bellus Health Inc. - a GSK companyNCT03979638Written as BLU-5937
- BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food EffectCompletedPhase 1Bellus Health Inc. - a GSK companyNCT03638180Written as BLU-5937
Codes
What other systems call BLU-5937 · ClinicalTrials.gg INT001270
- MeSH (NLM) C000657411BLU-5937One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000657411 | BLU-5937 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.